Genmab A (GMAB) Equity Average: 2019-2021
- Genmab A's Equity Average rose 55.39% to $1.2 billion in Q2 2021 from the same period last year, while for Jun 2021 it was $1.2 billion, marking a year-over-year increase of 55.39%. This contributed to the annual value of $2.0 billion for FY2020, which is 59.69% up from last year.
- Latest data reveals that Genmab A reported Equity Average of $1.2 billion as of Q2 2021, which was up 0.00% from $1.2 billion recorded in Q4 2020.
- Over the past 5 years, Genmab A's Equity Average peaked at $1.3 billion during Q4 2019, and registered a low of $780.5 million during Q2 2020.
- In the last 3 years, Genmab A's Equity Average had a median value of $1.2 billion in 2020 and averaged $1.1 billion.
- As far as peak fluctuations go, Genmab A's Equity Average decreased by 17.25% in 2020, and later soared by 55.39% in 2021.
- Over the past 3 years, Genmab A's Equity Average (Quarterly) stood at $1.3 billion in 2019, then dropped by 3.44% to $1.2 billion in 2020, then surged by 55.39% to $1.2 billion in 2021.
- Its Equity Average was $1.2 billion in Q2 2021, compared to $1.2 billion in Q4 2020 and $780.5 million in Q2 2020.
